iBio initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of iBio (IBIO) with an Outperform rating and $5 price target The firm based its Outperform rating on its optimism for lead asset IBIO-610 to address key therapeutic challenges in the growing obesity market. Preclinical data validate the potential of 610 to drive both fat loss and lean mass preservation, supporting a highly differentiated and complementary profile vs. incumbent incretins, the analyst tells investors in a research note.